Association between p16 Promoter Methylation and Thyroid Cancer Risk: A Meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Thyroid cancer is a significant global health concern.
• The role of epigenetic modifications, such as promoter methylation, in thyroid carcinogenesis is an area of active research.
• p16 gene promoter methylation is a potential biomarker for various cancers.

Purpose of the Study:

• To conduct a meta-analysis to precisely assess the association between p16 promoter methylation and thyroid cancer risk.
• To synthesize evidence from multiple case-control studies.
• To provide a quantitative estimate of the relationship.

Main Methods:

• A systematic literature search was performed across PubMed, Web of Science, and CNKI databases.
• Seventeen case-control studies comprising 804 thyroid cancer cases and 487 controls were included.
• Random-effects model meta-analysis was employed to calculate odds ratios and assess heterogeneity and publication bias.

Main Results:

• The meta-analysis revealed a significantly higher frequency of p16 promoter methylation in thyroid cancer tissues/blood compared to normal tissues/blood (OR=5.46, 95% CI 3.12-9.55, P<0.0001).
• The results indicated small heterogeneity among the included studies.
• Publication bias was assessed using funnel plots.

Conclusions:

• p16 promoter methylation is significantly associated with an increased risk of thyroid cancer.
• The findings support p16 promoter methylation as a potential biomarker for thyroid cancer.
• Further research may explore the specific mechanisms linking p16 methylation to thyroid carcinogenesis.